




**FIMECS is Named One of  
“TOP10 BIOTECH STARTUPS IN APAC-2019” Companies**



Kanagawa, Japan, 8 October 2019 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has been named by STARTUPCITY as one of “TOP10 BIOTECH STARTUPS IN APAC-2019” companies. Please find FIMECS’ Start-up story in the following URL.

For more information:

<https://biotech-apac.startupcity.com/vendor/fimecs-drugging-undruggable-targets-cid-355-mid-38.html>

**About FIMECS, Inc.**

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. <https://www.fimecs.com/eng/>

**About STARTUP CITY**

<https://www.startupcity.com/about-us/>

###

**FIMECS, Inc. Media and Investor Contact:**

Yusuke Kohno, CFO and VP of Corporate Development  
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan  
TEL: +81-50-5328-9458  
E-mail: [info@fimecs.com](mailto:info@fimecs.com)